⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312784 | 0.54 | — | — | |
| SCHEMBL152393 | 0.50 | — | — | |
| SCHEMBL7752905 | 0.50 | — | — | |
| SCHEMBL22791768 | 0.48 | — | — | |
| SCHEMBL24516407 | 0.44 | — | — | |
| SCHEMBL14138851 | 0.44 | — | — | |
| SCHEMBL18916671 | 0.42 | — | — | |
| SCHEMBL23171942 | 0.42 | — | — | |
| SCHEMBL21421784 | 0.42 | — | — | |
| SCHEMBL21421657 | 0.42 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101312724-A | Tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-26 | — | — | CN | disclosed |
| EP-1931336-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2008-06-18 | — | — | EP | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
| US-20070117857-A1 | Substituted 3-amido-tetrahydro-indazolyl cannabinoid modulators | JANSSEN PHARMACEUTICA, N.V. | 2007-05-24 | — | — | US | disclosed |
| WO-2007038045-A1 | TETRAHYDRO-INDAZOLYL CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-04-05 | — | — | WO | disclosed |